据知情人士透露，生物制药巨头吉利德科学与生物技术公司Ouro Medicines的并购谈判已进入关键阶段。双方正就最终条款进行磋商，若谈判顺利，这项备受业界关注的交易可能在未来数日内正式对外公告。
此次潜在收购将强化吉利德在创新疗法领域的战略布局。Ouro Medicines专注于开发针对遗传疾病的基因编辑技术，其研发管线与吉利德在罕见病治疗领域的拓展方向高度契合。业内人士分析，这项交易若能达成，将创造超过十亿美元的价值空间。
市场观察人士指出，此举延续了吉利德近年来通过并购加速创新的战略路径。该公司此前已通过收购Kite Pharma等企业成功切入细胞治疗领域，而本次交易或将进一步巩固其在基因治疗赛道的前沿地位。随着谈判进入收官阶段，两家公司股价近日均呈现波动上行态势。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.